NEW YORK (GenomeWeb) – Biodesix today announced that its VeriStrat test has received a positive coverage decision from CareFirst Blue Cross Blue Shield.

VeriStrat is a blood-based proteomic test that helps guide treatment decisions for patients with non-small cell lung cancer.

CareFirst announced its position to extend coverage for the VeriStrat test in March and published a positive coverage policy earlier this week on its website, Biodesix said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.